A Study of XmAb®18087 in Subjects With NET and GIST

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions
Neuroendocrine TumorGastrointestinal Neoplasm
Interventions
BIOLOGICAL

XmAb18087

monoclonal bispecific antibody

Trial Locations (16)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

22908

University of Virginia, Charlottesville

30322

Emory University, Atlanta

32224

Mayo Clinic, Jacksonville

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

43210

James Cancer Center, Columbus

55905

Mayo Clinic, Rochester

60611

Northwestern Medicine, Chicago

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Anschutz Medical Campus, Aurora

85054

Mayo Clinic, Phoenix

90048

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

91010

City of Hope Medical Center, Duarte

94304

Stanford Cancer Center, Palo Alto

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Xencor, Inc.

INDUSTRY